Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Photocure ASA ( (PHCUF) ) is now available.
Photocure ASA has announced progress in its collaboration with Richard Wolf to develop a new high-definition flexible blue light cystoscope for global commercialization. An interim solution, compatible with existing equipment, is now available, addressing an unmet need in bladder cancer diagnostics. This temporary setup allows urology centers to perform blue light flexible cystoscopy for patient surveillance, pending the arrival of the advanced HD scope. This development reinforces Photocure’s strategic market positioning and strengthens its partnership with Richard Wolf, aiming to enhance bladder cancer management.
More about Photocure ASA
Photocure ASA, known as The Bladder Cancer Company, operates in the healthcare industry with a focus on delivering transformative solutions for bladder cancer diagnosis and management. Their primary product involves a technology that enhances cancer cell visibility, improving patient outcomes. The company is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange.
YTD Price Performance: -2.72%
Average Trading Volume: 810
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $140.4M
For an in-depth examination of PHCUF stock, go to TipRanks’ Stock Analysis page.
